Perlman S - Search Results

1

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.

Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Lynch DR, et al. Among authors: perlman s. Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan. Ann Clin Transl Neurol. 2018. PMID: 30656180 Free PMC article. Clinical Trial.

2

Friedreich's ataxia GAA repeat expansion in patients with recessive or sporadic ataxia.

Geschwind DH, Perlman S, Grody WW, Telatar M, Montermini L, Pandolfo M, Gatti RA. Geschwind DH, et al. Among authors: perlman s. Neurology. 1997 Oct;49(4):1004-9. doi: 10.1212/wnl.49.4.1004. Neurology. 1997. PMID: 9339680

3

Clinical feature profile of spinocerebellar ataxia type 1-8 predicts genetically defined subtypes.

Maschke M, Oehlert G, Xie TD, Perlman S, Subramony SH, Kumar N, Ptacek LJ, Gomez CM. Maschke M, et al. Among authors: perlman s. Mov Disord. 2005 Nov;20(11):1405-12. doi: 10.1002/mds.20533. Mov Disord. 2005. PMID: 16037936

4

Measuring Friedreich ataxia: complementary features of examination and performance measures.

Lynch DR, Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Wilson RB, Balcer LJ. Lynch DR, et al. Among authors: perlman s. Neurology. 2006 Jun 13;66(11):1711-6. doi: 10.1212/01.wnl.0000218155.46739.90. Neurology. 2006. PMID: 16769945 Clinical Trial.

5

Antioxidant use in Friedreich ataxia.

Myers L, Farmer JM, Wilson RB, Friedman L, Tsou A, Perlman SL, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Mathews KD, Balcer LJ, Lynch DR. Myers L, et al. J Neurol Sci. 2008 Apr 15;267(1-2):174-6. doi: 10.1016/j.jns.2007.10.008. Epub 2007 Nov 7. J Neurol Sci. 2008. PMID: 17988688 Free PMC article. Clinical Trial.

6

Health related quality of life measures in Friedreich Ataxia.

Epstein E, Farmer JM, Tsou A, Perlman S, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Mathews K, Wilson RB, Balcer LJ, Lynch DR. Epstein E, et al. Among authors: perlman s. J Neurol Sci. 2008 Sep 15;272(1-2):123-8. doi: 10.1016/j.jns.2008.05.009. Epub 2008 Jun 20. J Neurol Sci. 2008. PMID: 18571673

7

Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.

Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Balcer LJ, Wilson RB, Lynch DR. Friedman LS, et al. Among authors: perlman s. Mov Disord. 2010 Mar 15;25(4):426-32. doi: 10.1002/mds.22912. Mov Disord. 2010. PMID: 20063431 Free PMC article.

8

A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia.

Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. Deutsch EC, et al. Mol Genet Metab. 2010 Oct-Nov;101(2-3):238-45. doi: 10.1016/j.ymgme.2010.07.001. Epub 2010 Jul 8. Mol Genet Metab. 2010. PMID: 20675166 Free PMC article.

9

A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.

Lynch DR, Perlman SL, Meier T. Lynch DR, et al. Arch Neurol. 2010 Aug;67(8):941-7. doi: 10.1001/archneurol.2010.168. Arch Neurol. 2010. PMID: 20697044 Clinical Trial.

10

Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).

Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, Rummey C, Meier T, Lynch DR. Lagedrost SJ, et al. Among authors: perlman sl. Am Heart J. 2011 Mar;161(3):639-645.e1. doi: 10.1016/j.ahj.2010.10.038. Epub 2011 Jan 31. Am Heart J. 2011. PMID: 21392622 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,231 results

Search Page